Saeed Rafii
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Cancer Research top 10%
Papers in
- Oncology 23
- PARP inhibition in cancer therapy 7
- HER2/EGFR in Cancer Research 5
- Cancer Immunotherapy and Biomarkers 4
- Cancer Treatment and Pharmacology 3
-
- DNA Repair Mechanisms 4
- Co-authors
- Zev A. Wainberg (4 shared papers)Alexandra Drakaki (2 shared papers)Winston Tan (1 shared paper)Tyler J. Curiel (2 shared papers)Omid Hamid (2 shared papers)John A. Blake-Haskins (2 shared papers)Peter H. O’Donnell (2 shared papers)Michael S. Gordon (2 shared papers)
- Journals
- Journal of Clinical Oncology (10 papers)Human Molecular Genetics (3 papers)Annals of Oncology (3 papers)Cancer Research (2 papers)Breast Cancer Research (2 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Saeed Rafii
34 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Oncology 1.0k
- Cancer Research 194
- Reproductive Medicine 106
- Obstetrics and Gynecology 95
- Immunology 242
Countries citing papers authored by Saeed Rafii
This map shows the geographic impact of Saeed Rafii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saeed Rafii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saeed Rafii more than expected).
Fields of papers citing papers by Saeed Rafii
This network shows the impact of papers produced by Saeed Rafii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saeed Rafii. The network helps show where Saeed Rafii may publish in the future.
Co-authors
The 25 scholars most cited alongside Saeed Rafii, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer Hit paper breakdown → | 2016 | 661 |
| 2 | 2017 | 314 | |
| 3 | 2017 | 108 | |
| 4 | 2002 | 96 | |
| 5 | 2019 | 48 | |
| 6 | 2006 | 33 | |
| 7 | 2022 | 30 | |
| 8 | 2015 | 28 | |
| 9 | 2014 | 28 | |
| 10 | 2015 | 27 | |
| 11 | 1990 | 23 | |
| 12 | 2017 | 18 | |
| 13 | 2003 | 13 | |
| 14 | 2016 | 11 | |
| 15 | 2022 | 9 | |
| 16 | 2017 | 8 | |
| 17 | 2016 | 5 | |
| 18 | 2018 | 5 | |
| 19 | 2016 | 4 | |
| 20 | 2025 | 3 |
About Saeed Rafii
Saeed Rafii is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Genetics and Reproductive Medicine, having authored 34 papers that have together received 1.5k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (7 papers), HER2/EGFR in Cancer Research (5 papers), BRCA gene mutations in cancer (5 papers), Ovarian cancer diagnosis and treatment (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), DNA Repair Mechanisms (4 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Oncology (1.0k citations), Cancer Research (194 citations), Reproductive Medicine (106 citations), Obstetrics and Gynecology (95 citations) and Immunology (242 citations). Saeed Rafii has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Zev A. Wainberg, Alexandra Drakaki, Winston Tan, Tyler J. Curiel, Omid Hamid, John A. Blake-Haskins, Peter H. O’Donnell, Michael S. Gordon, Sunil Sharma and Christophe Massard. Their work appears in journals such as Journal of Clinical Oncology, Human Molecular Genetics, Annals of Oncology, Cancer Research and Breast Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.